Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma-Reference-Cited by-同舟云学术

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Published:2024-01-25 Issue:4 Volume:390 Page:301-313
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Sonneveld Pieter¹,Dimopoulos Meletios A.¹,Boccadoro Mario¹,Quach Hang¹,Ho P. Joy¹,Beksac Meral¹,Hulin Cyrille¹,Antonioli Elisabetta¹,Leleu Xavier¹,Mangiacavalli Silvia¹,Perrot Aurore¹,Cavo Michele¹,Belotti Angelo¹,Broijl Annemiek¹,Gay Francesca¹,Mina Roberto¹,Nijhof Inger S.¹,van de Donk Niels W.C.J.¹,Katodritou Eirini¹,Schjesvold Fredrik¹,Sureda Balari Anna¹,Rosiñol Laura¹,Delforge Michel¹,Roeloffzen Wilfried¹,Silzle Tobias¹^ORCID,Vangsted Annette¹,Einsele Hermann¹,Spencer Andrew¹,Hajek Roman¹,Jurczyszyn Artur¹,Lonergan Sarah¹,Ahmadi Tahamtan¹,Liu Yanfang¹,Wang Jianping¹,Vieyra Diego¹,van Brummelen Emilie M.J.¹,Vanquickelberghe Veronique¹,Sitthi-Amorn Anna¹,de Boer Carla J.¹,Carson Robin¹,Rodriguez-Otero Paula¹,Bladé Joan¹,Moreau Philippe¹

Affiliation:

1. From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) — all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of...

Funder

European Myeloma Network in collaboration with Janssen Research & Development, LLC

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2312054

Reference23 articles.

1. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

2. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

3. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

4. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision medicine for multiple myeloma: The case for translocation (11;14);Cancer Treatment Reviews;2024-11

2. Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients;Blood Cancer Journal;2024-09-13

3. The 5T's of health disparities in multiple myeloma in Latin America;Current Opinion in Oncology;2024-09-09

4. Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma;BMC Cancer;2024-09-09

5. Induction prior to autologous haematopoietic cell transplantation in multiple myeloma;British Journal of Haematology;2024-09-09